NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading CSTL? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround opportunity, as CSTL aims to improve its financial metrics despite recent losses. The current thesis state is mixed, reflecting uncertainty in execution and market conditions.
The market seems to have priced in a low expectations gap, indicating that CSTL is viewed as relatively cheap compared to its peers. However, the valuation reflects a justified stance given the company's ongoing losses and weak recent performance.
Fundamentals are likely to remain under pressure in the near term, with management struggling to achieve positive net income and improve operating income. The recent financial performance has been weak, and while revenue guidance has been raised, execution remains uncertain.
The long-term thesis hinges on sector performance, particularly the results and guidance from major players like TMO, DHR, and IDXX. If these companies continue to perform well, it could provide a favorable backdrop for CSTL; conversely, any negative trends in these bellwethers could adversely affect CSTL's outlook.
Over the next 1 to 3 years, CSTL's performance will depend heavily on both its internal execution and external sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results show trends in revenue, operating income, and net income. They help assess performance.
Confirms one read:Earnings results show revenue growth and improved income metrics.
Confirms the other:Earnings results show more drops in revenue and income metrics.
Why it matters: Confirming the raised revenue guidance shows the company's growth momentum is on track.
Confirms:Q2 2026 revenue reported within the range of $345-355 million.
Disproves:Q2 2026 revenue reported below $345 million.
Why it matters: Better operating income means better cost management. This is key for making more money in the future.
Confirms:Operating income improves to less than -$15M in the next quarter.
Disproves:Operating income worsens to more than -$18M in the next quarter.
Why it matters: Positive net income would be a big turnaround for the company. It is key for long-term success.
Confirms:Net income turns positive in Q2 2026.
Disproves:Net income remains negative, worsening from -$14.52M in Q1 2026.
Why it matters: If sector revenue growth speeds up, it could help Castle Biosciences. A strong sector can lift individual companies.
Confirms:Sector revenue growth shows a year-over-year increase above 10%.
Disproves:Sector revenue growth is slowing down and is now below 10%.
Why it matters: Higher revenue guidance shows confidence in growth. This is true even with recent revenue drops.
Confirms:Management raises 2026 revenue guidance to $355M or higher.
Disproves:Management keeps or lowers 2026 revenue guidance to below $345M.
